Harmony Biosciences Holdings, Inc.
HRMY$904M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaPLYMOUTH MEETING268 employees
Drugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Jul 15, 2026
15wMarket Overview
Stock performance and key metrics
HRMY News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
Pitolisant tablet
Prader-Willi Syndrome
Pitolisant
Idiopathic Hypersomnia
Open-label pitolisant
Idiopathic Hypersomnia
Pitolisant Oral Tablet
Myotonic Dystrophy 1
Pitolisant oral tablets
Prader-Willi Syndrome
ZYN002
22Q11.2 Deletion Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pitolisant tablet | Phase 3 | Prader-Willi Syndrome | - | - |
Pitolisant | Phase 3 | Idiopathic Hypersomnia | - | - |
Open-label pitolisant | Phase 3 | Idiopathic Hypersomnia | - | - |
Pitolisant Oral Tablet | Phase 2 | Myotonic Dystrophy 1 | - | - |
Pitolisant oral tablets | Phase 2 | Prader-Willi Syndrome | - | - |
ZYN002 | Phase 2 | 22Q11.2 Deletion Syndrome | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply